Mumbai-based drugmaker Lupin on Thursday said it has received an approval from US health regulator Food and Drug Association (FDA) to market its generic drug used in treating the Alzheimer’s disease. The company’s product is a generic version of Allergan’s Namenda XR capsules, whose sales in the US accounted for $1.22 billion in the year ended June.